In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. In the autumn the University’s research outputs will be available to search and browse via a new Research Portal. Until then the University’s full publication record can be accessed via a temporary portal and the old eScholar content is available to search and browse via this archive.

Related resources

Full-text held externally

Investigational VEGF antagonists for psoriasis.

Crawshaw, A A; Griffiths, C E M; Young, H S

Expert opinion on investigational drugs. 2012;21(1):33-43.

Access to files

Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

Full-text held externally

Abstract

INTRODUCTION: Vascular endothelial growth factor (VEGF) mediates angiogenesis consequent to binding to VEGF receptors (VEGFRs) and is upregulated in patients with psoriasis. VEGF is also upregulated in other diseases characterised by angiogenesis including proliferative retinopathy and cancer. Several VEGF antagonists have been approved for the treatment of these conditions and may also have the potential to treat psoriasis. AREAS COVERED: A PubMed literature search was performed to identify preclinical and clinical research regarding investigational VEGF antagonists for the treatment of psoriasis. Various agents have been reviewed including monoclonal antibodies against VEGF and VEGFRs, decoy anti-VEGF receptors and tyrosine kinase inhibitors that block the effects of VEGF/VEGFR binding. EXPERT OPINION: Several investigational drugs have demonstrated potential to treat psoriasis. Clinical observations of psoriasis remission following administration of bevacizumab, sunitinib and sorafenib in cancer patients are encouraging. Of particular interest is a novel anti-VEGF/anti-TNF-α decoy receptor (Valpha), whose dual action could be beneficial given the numerous pathogenetic pathways in psoriasis. A topical tyrosine kinase inhibitor also has potential given the cost and safety advantages conferred by this mode of administration. More research is warranted both in the prototypical drugs and in those already marketed for other indications.

Bibliographic metadata

Type of resource:
Content type:
Publication type:
Published date:
Abbreviated journal title:
ISSN:
Place of publication:
England
Volume:
21
Issue:
1
Pagination:
33-43
Digital Object Identifier:
10.1517/13543784.2012.636351
Pubmed Identifier:
22088218
Access state:
Active

Institutional metadata

University researcher(s):
Academic department(s):

Record metadata

Manchester eScholar ID:
uk-ac-man-scw:180714
Created by:
Griffiths, Christopher
Created:
1st November, 2012, 13:08:59
Last modified by:
Griffiths, Christopher
Last modified:
1st March, 2014, 13:17:46

Can we help?

The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.